Kirchgraber Paul R 4
4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed Feb 6, 2023
Insider Transaction Report
Form 4
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
- Tax Payment
Common Stock
2023-02-02$254.99/sh−141$35,954→ 13,332 total - Exercise/Conversion
Restricted Stock Unit
2023-02-02−443→ 2,454 total→ Common Stock (443 underlying) - Exercise/Conversion
Common Stock
2023-02-02+443→ 13,473 total
Footnotes (4)
- [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022.
- [F4]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.